Denteric is developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis) and related species. In so doing, its primary goal is to provide options to treat and prevent severe periodontal disease and its complications, a condition which affects approximately 1 in 10 people globally. In time, it is also possible that this approach will have relevance in additional medical conditions which are associated with P gingivalis and related species.
https://www.denteric.com/
https://www.denteric.com/
Investors 1
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
Mentions in press and media 3
| Date | Title | Description |
| 26.03.2026 | Denteric Announces FDA IND Clearance for GPV381, a First-in-Class Therapeutic Vaccine Targeting Gingipain-Driven Inflammation in Periodontitis | Melbourne, Australia – Denteric today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for GPV381, a first-in-class therapeutic vaccine targeting gingipain toxins, key ups... |
| 18.04.2024 | Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" | MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited ... |
| 26.09.2019 | $14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease | A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd. The company was set-up to develop and commercialis... |